Dycom Industries reported its fourth quarter results for fiscal 2025, posting an adjusted earnings per share (EPS) of $1.17, surpassing the estimate of $0.90. The company achieved sales of $1.08 billion, exceeding the forecast of $1.03 billion. Additionally, Dycom's net income for the quarter was $32.67 million, and it holds a backlog of $7.76 billion. Looking ahead, Dycom anticipates contract revenues between $1.16 billion and $1.2 billion for the first quarter of fiscal 2026, with an adjusted EBITDA forecast of $130.6 million to $140.6 million and diluted EPS ranging from $1.50 to $1.73 per share. Meanwhile, Teladoc Health reported a fourth quarter revenue of $640.5 million, slightly above the estimate of $639.6 million, but recorded a net loss of $48.4 million, leading to a GAAP EPS of -$0.28, which missed the expected -$0.23. For the full year 2024, Teladoc's revenue was $2.57 billion, a decrease of 1% year-over-year, alongside a net loss of $1 billion. The company provided guidance for 2025, expecting revenue between $2.47 billion and $2.58 billion, with an adjusted EBITDA forecast of $278 million to $319 million. Teladoc's shares fell by 12.2% following the release of its results and disappointing revenue outlook.